Kuan Gandelman

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. doi request reprint Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies
    Kuan Gandelman
    Pfizer Inc, New York, NY 10017, USA
    Am J Ther 19:164-73. 2012
  2. ncbi request reprint The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial
    Kuan Gandelman
    Clinical Pharmacology, Pfizer Inc, New York, NY 10017, USA
    J Clin Psychiatry 70:58-62. 2009
  3. pmc An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia
    Kuan Gandelman
    Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA
    Pediatr Cardiol 32:433-41. 2011
  4. pmc Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects
    Bimal Malhotra
    Pfizer Inc, New York, NY, USA
    Br J Clin Pharmacol 72:263-9. 2011
  5. doi request reprint Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine
    Bimal Malhotra
    Pfizer Inc, 685 3rd Avenue, New York, NY 10017, USA
    J Clin Pharmacol 49:477-82. 2009
  6. pmc Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers
    Bimal Malhotra
    Pfizer Inc, New York, NY, USA
    Br J Clin Pharmacol 72:257-62. 2011
  7. ncbi request reprint Pharmacokinetics of an extended release formulation of alprazolam (Xanax XR) in healthy normal adolescent and adult volunteers
    Paul Glue
    Pfizer, Inc, New York, NY 10017, USA
    Am J Ther 13:418-22. 2006
  8. doi request reprint Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism
    Kuan Gandelman
    Pfizer Inc, 235 East 42nd St, New York, NY 10017, USA
    J Clin Pharmacol 51:229-36. 2011

Detail Information

Publications8

  1. doi request reprint Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies
    Kuan Gandelman
    Pfizer Inc, New York, NY 10017, USA
    Am J Ther 19:164-73. 2012
    ..These data therefore demonstrate that dosing considerations in the current labels for atorvastatin are similar for Asian compared with Caucasian subjects...
  2. ncbi request reprint The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial
    Kuan Gandelman
    Clinical Pharmacology, Pfizer Inc, New York, NY 10017, USA
    J Clin Psychiatry 70:58-62. 2009
    ....
  3. pmc An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia
    Kuan Gandelman
    Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA
    Pediatr Cardiol 32:433-41. 2011
    ..Atorvastatin also was well tolerated in this population...
  4. pmc Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects
    Bimal Malhotra
    Pfizer Inc, New York, NY, USA
    Br J Clin Pharmacol 72:263-9. 2011
    ..Currently, no information is available on whether dose adjustment is necessary when fesoterodine is administered with a moderate CYP3A4 inhibitor...
  5. doi request reprint Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine
    Bimal Malhotra
    Pfizer Inc, 685 3rd Avenue, New York, NY 10017, USA
    J Clin Pharmacol 49:477-82. 2009
    ..43-0.54 ng/mL) is comparable across all groups. In conclusion, because of the involvement of both metabolic and renal elimination pathways, only modest increases in 5-HMT exposures are observed in patients with renal impairment...
  6. pmc Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers
    Bimal Malhotra
    Pfizer Inc, New York, NY, USA
    Br J Clin Pharmacol 72:257-62. 2011
    ..Preclinical in vitro studies suggest that fesoterodine or 5-hydroxymethyl tolterodine are not likely to affect warfarin metabolism, but a lack of interaction has not been demonstrated in a clinical study...
  7. ncbi request reprint Pharmacokinetics of an extended release formulation of alprazolam (Xanax XR) in healthy normal adolescent and adult volunteers
    Paul Glue
    Pfizer, Inc, New York, NY 10017, USA
    Am J Ther 13:418-22. 2006
    ..The most common adverse event was somnolence, which occurred in a dose-related manner. Based on the similar pharmacokinetic profiles, dosing of Xanax XR should be similar in adolescents and adults...
  8. doi request reprint Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism
    Kuan Gandelman
    Pfizer Inc, 235 East 42nd St, New York, NY 10017, USA
    J Clin Pharmacol 51:229-36. 2011
    ..The clinical significance of the decreased linezolid levels is unclear. Linezolid and rifampin administered alone or in combination was generally safe and well tolerated...